Skip to main content

Myopic Astigmatism

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
TENEO 317 Model 2N/A1 trial
Active Trials
NCT07377474Not Yet Recruiting32Est. Sep 2027
STAAR Surgical
STAAR SurgicalCA - Lake Forest
1 program
Visian TICLN/A1 trial
Active Trials
NCT04516772Completed125Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bausch HealthTENEO 317 Model 2
STAAR SurgicalVisian TICL

Clinical Trials (2)

Total enrollment: 157 patients across 2 trials

NCT07377474Bausch HealthTENEO 317 Model 2

A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism

Start: Apr 2026Est. completion: Sep 202732 patients
N/ANot Yet Recruiting

STAAR Visian Toric ICL Post-Approval Study

Start: Jul 2020Est. completion: Dec 2024125 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.